WINDLAS1,135.00

Windlas Biotech Limited

· Pharma & Health
AnnualQuarterly₹ CrorePeersHESTERBIOINDOCOSAIPARENTSYNCOMFPANACEABIONGLFINEHIKALJAGSNPHARMMcap ₹2,396 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Revenue from Operations631.0759.9904.1
Other Income13.518.017.8
Total Income644.4777.9921.9
Expenses
+ Cost of Materials Consumed3.02.312.5
+ Purchases of Stock-in-Trade383.6491.1537.7
+ Changes in Inventories9.6-21.57.1
+ Employee Benefit Expense87.5122.9152.1
+ Finance Costs1.14.44.8
+ Depreciation & Amortisation13.428.030.7
+ Other Expenses69.271.090.0
Total Expenses567.3698.1834.9
EBITDA78.294.1104.7
EBIT64.766.174.0
Profit
PBT before Exceptional Items77.179.887.0
Pretax Income77.179.887.0
+ Current Tax17.418.320.7
+ Deferred Tax1.50.5-0.2
Tax Expense18.918.820.5
Net Income58.261.066.5
+ Net Income — Continuing Ops58.261.066.5
+ Other Comprehensive Income-0.2-0.50.1
Total Comprehensive Income57.960.466.6
Per Share
Basic EPS27.9729.1931.60
Diluted EPS27.8828.8731.15
Other Comprehensive Income — detail
+ Other Comprehensive Income-0.50.1
+ Items NOT to be Reclassified to P&L-0.3-0.70.1
+ Tax on Items NOT to be Reclassified-0.20.0
+ Tax on Items NOT to be Reclassified — alt tag-0.1
+ Items to be Reclassified to P&L-0.00.0
Per Share — as-filed variants
Basic EPS — Continuing Operations27.9729.1931.60
Diluted EPS — Continuing Operations27.8828.8731.15
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit234.8288.0346.9
Gross Margin %37.2137.9038.37
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)77.179.887.0
Net Income Adj (tax-effected)58.261.066.5
EPS Adj27.9729.1931.60
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value5.005.005.00
Paid Up Equity Capital10.410.510.6
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.